INS and metabolic syndrome: Fasting glucose lower, fasting insulin, and 2-hour postchallenge glucose higher in patients with CAH vs controls; elevated HOMA-IR more often in patients with CAH (62.5%) vs controls (18.8%); impaired fasting glucose in 1 patient (5%) with SW; impaired glucose tolerance in 3 patients (25%) with SV; no cases of metabolic syndrome in patients with CAH; inverse correlation between insulin and testosterone in patients with CAH; no correlation between glucose homeostasis markers and glucocorticoid type and dose